Corporate ActionJun 24, 2026, 04:13 PM
Serina Therapeutics Increases Authorized Shares to 125M
AI Summary
Serina Therapeutics, Inc. announced that its stockholders approved an increase in authorized common stock from 40,000,000 to 125,000,000 shares at the 2026 Annual Meeting. Stockholders also approved an amendment to the 2024 Equity Incentive Plan to add 2,000,000 shares, and approved proposals related to the conversion of Series A Preferred Stock and the issuance of common stock for Private Placement Securities. Additionally, three directors were re-elected, and Frazier & Deeter, LLC was ratified as the independent auditor.
Key Highlights
- Authorized common stock increased from 40,000,000 to 125,000,000 shares.
- 2,000,000 additional shares approved for the 2024 Equity Incentive Plan.
- Stockholders approved the conversion of Series A Preferred Stock into common stock.
- Stockholders approved the issuance of common stock for Private Placement Securities.
- Three directors (Gregory H. Bailey, Richard Marshall, Jay Venkatesan) were re-elected.
- Advisory vote on executive compensation was approved.
- Advisory vote for annual frequency of Say-on-Pay was approved.
- Frazier & Deeter, LLC ratified as independent auditors for 2026.
Price Impact
More from SER